MedTrace Logo

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

NCT05736978 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-03-15

No results posted yet for this study

Summary

This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.

Conditions

Interventions

DRUG

Azacitidine

75mg/m2 d1-7

DRUG

Venetoclax

d1 100mg, d2 200mg, d3-28 400mg

DRUG

Selinexor

if MRD positive in C1D14, selinexor 60mg D15, D22

Sponsors & Collaborators

  • Shanghai Tong Ren Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2025-03-01
Completion
2027-03-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05736978 on ClinicalTrials.gov